TTR and peripheral nervous system disorder: In 2018, the first siRNA drug Onpattro (aka Patisiran), which targets transthyretin (Ttr) gene for the treatment of peripheral nerve disease in adults was approved by the U.S. Food and Drug Administration (FDA).